| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
3
1
3
5
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
B+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 42.49 | 42.49 |
| Stocks | 56.32 | 56.32 |
| Bonds | 0.0 | 0.0 |
| Other | 1.2 | 1.2 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 0.0 | 0.0 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 01.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 01.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 21.82 | 10.13 |
| Gilead Sciences Inc | GILD | 36.53 | 9.23 |
| AbbVie Inc | ABBV | 35.69 | 8.97 |
| Celgene Corporation | CELG | 48.67 | 6.48 |
| Biogen Idec Inc | BIIB | 46.43 | 5.71 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 2.83 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.71 | 2.03 |
| Life Technologies Corp | LIFE | 50.05 | 1.72 |
| Vertex Pharmaceuticals | VRTX | 83.37 | 1.49 |
| Biomarin Pharmaceutical, Inc. | BMRN | 29.43 | 1.06 |
